Study study type PathologyT1T0Patientssample sizesROB Results

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
avelumab plus axitinib
JAVELIN Renal 101( PDL1>1%), 2019
  NCT02684006
RCTmRCC - L1 - PDL1 positiveAvelumab plus AxitinibSunitinibpatients with previously untreated advanced renal cell carcinoma (PDL1>1% population)270 / 290some concern
conclusif
  • suggested 31 % decrease in deaths (OS) (PE)
  • demonstrated 39 % decrease in progression or deaths (PFS) (PE)
  • suggested 38 % decrease in PFS (extension)